Biodesign of a skeletal muscle flap as a model for cardiac assistance.
In using autologous muscles for cardiac assistance, it is crucial to reduce ischemia-reperfusion injury in the surgically traumatized skeletal muscle. In adult sheep, we developed a simple model of surgically designed 2 latissimus dorsi muscle leaflets by modifying the vascular supply to these leaflets. Three pockets with graded injury were established, and muscle morphology and vascular remodeling were monitored in 3 experimental groups: muscle leaflets without any treatment (Group 1, n = 6) that served as controls; muscle leaflets integrated with a fibrin interlayer (Group 2, n = 6); and leaflets integrated with fibrin and entrapped pyrrolostatin (Group 3, n = 6). We applied the fibrinogen and thrombin solutions, which polymerize to form a three-dimensional meshwork joining the tissues, creating a provisional matrix for angiogenesis, and acting as a delivery depot for agents aimed at minimizing ischemia-reperfusion lesion formation. After 2 months, the muscle leaflets biointegrated with the fibrin interface showed none of the signs of necrosis or ischemia-reperfusion lesions seen in the controls. Although no angiogenic factors were incorporated, the fibrin interlayer rapidly (<2 weeks) became a densely vascularized tissue replete with a voluminous capillary network. In contrast, controls showed poor bonding between the tissues, muscle fiber deterioration, and a compromised vascular network. Muscle structure was best preserved and angiogenesis was greatest when pyrrolostatin, a free radical scavenger, was added to the fibrin meshwork to reduce damage caused by overproduction of free radicals. This newly designed model will be useful to study many current approaches in cardiovascular biology, from pharmaceuticals to gene therapy, which might prove advantageous in muscle-designed cardiac assistance.
Nikolaychik
V V
VV
University of Wisconsin Medical School and Milwaukee Heart Project, Milwaukee, Wisconsin, USA.
Chekanov
V S
VS
Hernandez
I
I
Silverman
M D
MD
Lelkes
P I
PI
D000818:Animals; D002196:Capillaries / Q000648:ultrastructure; D018421:Cardiomyoplasty; D003692:Delayed-Action Preparations; D005337:Fibrin / Q000627:therapeutic use; D005340:Fibrinogen / Q000627:therapeutic use; D016166:Free Radical Scavengers / Q000627:therapeutic use; D005609:Free Radicals / Q000037:antagonists & inhibitors; D006085:Graft Survival; D008854:Microscopy, Electron; D018485:Muscle Fibers, Skeletal / Q000648:ultrastructure; D018482:Muscle, Skeletal / Q000098:blood supply / Q000473:pathology / Q000637:transplantation*; D018919:Neovascularization, Physiologic; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D015427:Reperfusion Injury / Q000517:prevention & control; D012756:Sheep; D013524:Surgical Flaps / Q000098:blood supply / Q000473:pathology*; D013917:Thrombin / Q000627:therapeutic use; D014014:Tissue Adhesives / Q000627:therapeutic use; D014182:Transplantation, Autologous
D003692:Delayed-Action Preparations; D016166:Free Radical Scavengers; D005609:Free Radicals; D014014:Tissue Adhesives; C082418:pyrrolostatin; D005337:Fibrin; D005340:Fibrinogen; D011392:Proline; D013917:Thrombin